Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

943P - Long-term outcome of the oldest-old patients (85 years or older) underwent proton beam therapy for hepatocellular carcinoma

Date

16 Sep 2021

Session

ePoster Display

Topics

Radiation Oncology

Tumour Site

Hepatobiliary Cancers

Presenters

Takashi Iizumi

Citation

Annals of Oncology (2021) 32 (suppl_5): S818-S828. 10.1016/annonc/annonc677

Authors

T. Iizumi1, T. Okumura2, K. Maruo3, K. Baba1, M. Murakami1, S. Shimizu1, T. Saito1, M. Nakajima1, H. Makishima2, H. Numajiri1, M. Mizumoto2, K. Nakai2, H. Sakurai2

Author affiliations

  • 1 Department Of Radiation Oncology, Proton Beam Therapy Center, Tsukuba Unviersity Hospital, 305-8576 - Tsukuba/JP
  • 2 Department Of Radiation Oncology, University of Tsukuba, 305-8576 - Tsukuba/JP
  • 3 Department Of Biostatistics, University of Tsukuba, 305-8576 - Tsukuba/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 943P

Background

The incidence rate of HCC in the oldest-old (85 years or older) patients is rising along with the global progression of aging society. However, the optimal oncological management of this population has to be elucidated due to the paucity of published studies about very elderly patients. Proton beam therapy (PBT) is a less invasive and effective treatment for HCC. However, long-term outcome of elderly patients underwent PBT for HCC has not been reported. The purpose of our study is to present the outcome and toxicity of PBT for the oldest-old patients with HCC.

Methods

This is a single institutional, retrospective study of 201 elderly patients treated with PBT for HCC from November 2001 to November 2014. Of which, 98 patients (48.8%) were young-old (age: 75-80), 74 (36.8%) were old-old (age: 80-85), and 29 (14.4%) were the oldest-old (age ≥ 85). Overall survival (OS) and progression-free survival (PFS) rates were estimated by Kaplan-Meier method and log-rank test was used for comparisons. Cumulative incidence function (CIF) of local recurrence (LR) was computed by competing risk analysis with death as a competing event. Toxicities were graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events version 4.0.

Results

The median follow-up period was 34.9 months. The median age of all patients was 80 (range, 75-92). The median size of a tumor was 3.9 (range, 1.0-15.5) cm. The majority of patients had Eastern Cooperative Oncology Group performance status 0-1 (n=182, 90.6%), solitary tumor (n=145, 72.1%), hepatitis C virus as an underlying cause (n=123, 61.2%), and no previous treatment history (n=106, 52.7%). OS rates at 1, 3, and 5 years were 89.7%, 54.1%, and 32.1%. PFS were 34.4%, 32.9%, 10.5%. At 1, 3, and 5 years, the CIF of LR were 4.7% [1.7-7.6%], 9.6% [5.4-13.9%], and 11.4% [6.8-16.0%], respectively. No significant difference was observed in OS rates between three subgroups (P = 0.4). No grade 3 or worse toxicity was observed.

Conclusions

We observed long-term survival and local control in the oldest-old patients underwent PBT for HCC. Our results indicate that PBT is effective and tolerable for patients with HCC in the oldest-old age.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.